Add-on Acquisition • Life Science

AgomAb Therapeutics Acquires Origo Biopharma

On October 28, 2021, AgomAb Therapeutics acquired life science company Origo Biopharma

Acquisition Context

This is AgomAb Therapeutics’ 1st transaction in the Life Science sector.
This is AgomAb Therapeutics’ 1st transaction in Spain.

Explore All 3109 Add-on Acquisition Life Science Deals - Search the Database Free

M&A Deal Summary
Date	October 28, 2021
Target	Origo Biopharma
Sector	Life Science
Buyer(s)	AgomAb Therapeutics
Deal Type	Add-on Acquisition

Target Company

Origo Biopharma

Fonte Diaz, Spain

Origo Biopharma is a clinical stage biotechnology company developing organ-restricted small molecule drug candidates targeting the transforming growth factor beta (TGF-β) pathway for the treatment of fibrosis-related disorders. Origo Biopharma is based in Fonte Diaz, Spain.

Explore More Deals

Browse All 215,156 Deals

FILTER BY

Buyer Type (PE or Strategic)
Deal Size ($10M to $10B+)
Sector (60 Sectors)
Deal Type
Geography
& More

Search Free

Buyer Overview 1

Buyer

AgomAb Therapeutics

Antwerpen, Belgium

Category	Company
Founded	2017
Sector	Life Science

DESCRIPTION

AgomAb Therapeutics is a biotherapeutics company developing agonistic antibodies for the regeneration of damaged tissues. AgomAb Therapeutics was founded in 2017 and is based in Antwerpen, Belgium.

Deal Context for Buyer	#
Overall	1 of 1
Sector: Life Science	1 of 1
Type: Add-on Acquisition	1 of 1
Country: Spain	1 of 1
Year: 2021	1 of 1

Explore Related M&A Activity

Life Science M&A - Add-on Acquisition M&A Deals - Spain M&A - 2021 M&A